GlycoNex Inc. is a Taiwan-based company principally engaged in the development and licensing of anti-cancer monoclonal antibodies, as well as the provision of carbohydrate antigen and protein drug related commission services. The Company is mainly involved in the development of anti-cancer monoclonal antibody new drugs and bio-similar drugs, as well as the licensing of monoclonal antibody targets and carbohydrate antigen and protein drug related services. The Company distributes its products in domestic market and to overseas markets, such as the rest areas of Asia.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-06-11	27.75 NT$	+9.90%	2,831,120
26-06-10	25.25 NT$	+0.60%	205,179
26-06-09	25.10 NT$	0.00%	173,457
26-06-08	25.10 NT$	-3.83%	321,439
26-06-05	26.10 NT$	+0.19%	251,773

End-of-day quote Taipei Exchange

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Taipei Exchange Other stock markets 2026-06-11			5-day change	1st Jan Change
27.75 ^TWD	+9.90%		+6.53%	+7.77%

05-14	GlycoNex Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-14	GlycoNex, Inc Receives PMDA Approval To Initiate First-In-Human Phase 1 Trial Of GNX1021 In Gastrointestinal Cancers	CI

Market Cap	3.12B 98.63M 85.59M 78.89M 73.92M 138M 9.44B 141M 941M 364M 4.55B 370M 362M 15.83B	P/E Ratio 2024	-11.8x	P/E Ratio 2025	-11.9x
Enterprise Value	2.9B 91.69M 79.57M 73.34M 68.72M 128M 8.78B 131M 875M 339M 4.23B 344M 337M 14.71B	EV / Sales 2024	154x	EV / Sales 2025	67.8x
Free-Float	80.91%	Yield 2024 *	-	Yield 2025	-

05-14	GlycoNex Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-14	GlycoNex, Inc Receives PMDA Approval To Initiate First-In-Human Phase 1 Trial Of GNX1021 In Gastrointestinal Cancers	CI
03-23	GlycoNex Inc. And Nippon Kayaku Co., Ltd. Enters Collaboration To Advance Next-Generation ADC Candidate	CI
03-13	GlycoNex Incorporation Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12-08	GlycoNex Signs CDMO Service Agreement with Change Cure to Advance HMGB1-Targeted Antibody Program	CI
11-24	Glyconex, Inc. and Hokkaido University Hospital Launch Study to Advance Glycan-Directed ADC Development in Gastric Cancer	CI
11-14	GlycoNex Incorporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-10-29	GlycoNex announces last patient dosed in phase 3 trial of SPD8, a denosumab biosimilar for osteoporosis	RE
25-10-29	GlycoNex, Inc. Announces Last Patient Dosed in Phase 3 Trial of SPD8, a Denosumab Biosimilar for Osteoporosis	CI
25-08-13	GlycoNex Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-06-12	GlycoNex, Inc. Announces Publication of Preclinical Study on Gnx1021, A Novel Glycan-Targeted Adc for Gastric Cancer	CI
25-05-27	GlycoNex, Inc. Announces Publication of Research Involving Pro-Antibody, GNX201, in the International Journal of Biological Macromolecules	CI
25-05-12	GlycoNex Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2025	CI

1 day	+9.90%
1 week	+6.53%
Current month	+8.82%
1 month	+23.88%
3 months	+12.58%
6 months	+29.07%
Current year	+7.77%

GlycoNex Incorporation Stock

Stocks

4168

TW0004168000

Biotechnology & Medical Research

Valuation: GlycoNex Incorporation

Chart: GlycoNex Incorporation

Latest news : GlycoNex Incorporation

Press Releases: GlycoNex Incorporation

Quotes and Performance

Course Extremes

Managers and Directors: GlycoNex Incorporation

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	24.65	27.75
1 month	22.3	29
Current year	22.1	30
1 year	20.55	30.95
3 years	15.6	33.2
5 years	15.6	46.9
10 years	10.2	46.9

Manager	Title	Age	Since
Mei Chun Yang CEO	Chief Executive Officer	-	2018-12-31
Dih Fen Wu DFI	Director of Finance/CFO	-	2009-12-31
Yao Hua Lue IRC	Investor Relations Contact	-	2012-11-11

Director	Title	Age	Since
Tong Hsuan Chang CHM	Chairman	-	2001-01-31
Kao Chung Tsai BRD	Director/Board Member	64	-
Ling-Chun Tsai BRD	Director/Board Member	-	2012-05-24

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GLYCONEX INCORPORATION	+9.90%	+6.53%	+9.68%	-9.02%	98.63M
LONZA GROUP AG	+1.28%	+2.92%	-14.33%	-11.04%	42.96B
REVOLUTION MEDICINES, INC.	+3.50%	-4.15%	+265.85%	+484.30%	31.73B
IQVIA HOLDINGS INC.	-0.61%	-3.11%	+14.00%	-12.36%	30.22B
BEONE MEDICINES AG	-1.27%	-7.02%	-0.82%	+20.47%	28.94B
CELLTRION, INC.	-0.66%	-5.84%	+7.59%	+12.76%	23.87B
MEDPACE HOLDINGS, INC.	+2.01%	+3.57%	+57.15%	+128.55%	13.57B
EUROFINS SCIENTIFIC SE	+0.90%	0.00%	+7.45%	+9.00%	12.96B
ASCENDIS PHARMA A/S	+2.77%	-1.48%	-	-	13.39B
IONIS PHARMACEUTICALS, INC.	+0.68%	-1.74%	+103.98%	+81.60%	12.2B
Average	+1.85%	-1.16%	+50.06%	+78.25%	20.99B
Weighted average by Cap.	+0.87%	-2.39%	+53.63%	+92.96%

	2024	2025
Net sales	14.7M 464K 403K 371K 348K 650K 44.46M 664K 4.43M 1.72M 21.43M 1.74M 1.71M 74.52M	37.86M 1.2M 1.04M 957K 896K 1.67M 115M 1.71M 11.41M 4.42M 55.2M 4.49M 4.39M 192M
Net income	-230M -7.26M -6.3M -5.8M -5.44M -10.16M -695M -10.37M -69.23M -26.81M -335M -27.24M -26.65M -1.16B	-235M -7.43M -6.45M -5.94M -5.57M -10.41M -711M -10.62M -70.9M -27.45M -343M -27.89M -27.29M -1.19B
Net Debt	-442M -13.96M -12.12M -11.17M -10.47M -19.56M -1.34B -19.96M -133M -51.59M -645M -52.42M -51.29M -2.24B	-220M -6.94M -6.02M -5.55M -5.2M -9.72M -664M -9.92M -66.22M -25.64M -320M -26.05M -25.49M -1.11B